VPRIV (velaglucerase alfa) is a prescription medication used in the treatment of Gaucher disease, a rare genetic disorder characterized by the accumulation of glucocerebroside in various organs of the body, including the liver, spleen, bones, and bone marrow. This accumulation can lead to various symptoms such as anemia, bruising, enlarged liver or spleen, and bone pain or fractures. VPRIV is a form of enzyme replacement therapy (ERT) that works by replacing the deficient enzyme (glucocerebrosidase) in patients with Gaucher disease, helping to break down glucocerebroside and reduce its accumulation in the body's cells. Administered through intravenous infusion, VPRIV is specifically indicated for patients with Type 1 Gaucher disease, the most common form of the disorder. It has been approved by regulatory agencies in multiple countries, offering an essential treatment option for managing the symptoms and complications associated with Gaucher disease.